This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 MedTech Stocks Set to Rebound Post Coronavirus-Led Crisis
by Zacks Equity Research
Here are some MedTech stocks which are steadily inching toward a trend reversal after registering record declines over the past few weeks.
4 Stocks Countering Coronavirus Battle With Testing Kits
by Urmimala Biswas
While the market bloodbath is showing no signs of dissipating any time soon, investors might keep an eye on certain genetic testing and medical device companies.
5 Top Low-Beta Stocks Surged in March Defying Coronavirus
by Nalak Das
The global financial markets are currently witnessing one of the worst periods since the Great Depression due to the coronavirus-led crisis.
Here's Why You Should Hold on to LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about LabCorp (LH) on its strong segmental results in the fourth quarter of 2019.
Top Ranked Momentum Stocks to Buy for March 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 27th
QIAGEN Releases Coronavirus Test Kit in US on New FDA Policy
by Zacks Equity Research
QIAGEN (QGEN) releases test kits in the United States to speed up the diagnosis of coronavirus per the FDA's latest policy.
Here's Why You Should Add Hill-Rom Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on its strong domestic and international results in the first quarter of fiscal 2020.
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
Top Ranked Momentum Stocks to Buy for March 20th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 20th
QIAGEN Gets CE Nod for QIAstat-Dx Respiratory SARS-CoV-2 Test
by Zacks Equity Research
The regulatory clearance of this test has made QIAGEN (QGEN) a key player in coronavirus diagnosis.
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
by Debanjana Dey
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
3 Medical Stocks Poised to Trounce Market on Coronavirus Scare
by Urmimala Biswas
Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.
Is QIAGEN N.V. (QGEN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening
by Zacks Equity Research
BD (BDX) expects screening to ramp up by 1,000 per day once authorized.
QIAGEN's Coronavirus Test Kit Development Gets BARDA Funding
by Zacks Equity Research
QIAGEN (QGEN) receives support from the government to accelerate the development of the QIAstat-Dx test kit to detect the coronavirus causing virus.
BD MAX Gets CE Mark for Coronavirus Detection, Shares Up
by Zacks Equity Research
BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.
LabCorp (LH) Launches Test to Detect Presence of Coronavirus
by Zacks Equity Research
LabCorp (LH), with an aim to contain the outbreak of coronavirus, launches the LabCorp 2019 Novel Coronavirus (COVID-19), NAA test.
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
by Zacks Equity Research
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
3 MedTech Stocks to Rebound After Coronavirus-Led Recoil
by Sriparna Ghosal
As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Why Is Qiagen (QGEN) Up 19% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Mar 4, 2020
by Zacks Equity Research
Companies in the news are: SCON, OMER, QGEN, TLRY
Thermo Fisher (TMO) to Buy Molecular Diagnostics Major QIAGEN
by Zacks Equity Research
Thermo Fisher (TMO) expects QIAGEN's strong molecular diagnostics presence to complement its specialty diagnostics capabilities.
Will QIAGEN Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in QIAGEN.